About the Authors

David O'Sullivan

Contributed equally to this work with: David O'Sullivan, Laura Green

Affiliation School of Biological Sciences, Victoria University of Wellington, Wellington, New Zealand

Laura Green

Contributed equally to this work with: David O'Sullivan, Laura Green

Affiliation School of Biological Sciences, Victoria University of Wellington, Wellington, New Zealand

Sarrabeth Stone

Affiliation School of Biological Sciences, Victoria University of Wellington, Wellington, New Zealand

Pirooz Zareie

Affiliation School of Biological Sciences, Victoria University of Wellington, Wellington, New Zealand

Marie Kharkrang

Affiliation School of Biological Sciences, Victoria University of Wellington, Wellington, New Zealand

Dahna Fong

Affiliation School of Biological Sciences, Victoria University of Wellington, Wellington, New Zealand

Bronwen Connor

Affiliation Department of Pharmacology and Clinical Pharmacology, Centre for Brain Research, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand

Anne Camille La Flamme

anne.laflamme@vuw.ac.nz

Affiliations School of Biological Sciences, Victoria University of Wellington, Wellington, New Zealand, Malaghan Institute of Medical Research, Wellington, New Zealand

Competing Interests

The authors have read the journal's policy and the authors of this manuscript have the following competing interests: ACL, DO, and BC hold a patent for the use of risperidone and clozapine during MS.

Author Contributions

Conceived and designed the experiments: DO LG SS PZ MK DF BC ACL. Performed the experiments: DO LG SS PZ MK DF. Analyzed the data: DO LG SS PZ BC ACL. Contributed to the writing of the manuscript: DO LG ACL.